JP2017525354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525354A5 JP2017525354A5 JP2017505807A JP2017505807A JP2017525354A5 JP 2017525354 A5 JP2017525354 A5 JP 2017525354A5 JP 2017505807 A JP2017505807 A JP 2017505807A JP 2017505807 A JP2017505807 A JP 2017505807A JP 2017525354 A5 JP2017525354 A5 JP 2017525354A5
- Authority
- JP
- Japan
- Prior art keywords
- cell death
- high affinity
- programmed cell
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 63
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 63
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 102220496972 Platelet-activating factor acetylhydrolase 2, cytoplasmic_K53T_mutation Human genes 0.000 claims 18
- 102220058921 rs786202731 Human genes 0.000 claims 18
- 102200118229 rs34665886 Human genes 0.000 claims 17
- 102220161672 rs148219510 Human genes 0.000 claims 13
- 102220586093 Homeobox protein DLX-1_V39R_mutation Human genes 0.000 claims 10
- 102220354149 c.289C>A Human genes 0.000 claims 10
- 102220568823 Dual specificity mitogen-activated protein kinase kinase 1_G65V_mutation Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 102220249043 rs145159429 Human genes 0.000 claims 9
- 102220226094 rs17217723 Human genes 0.000 claims 9
- 102220311149 rs41271047 Human genes 0.000 claims 9
- 102220279022 rs955258267 Human genes 0.000 claims 9
- 102220507725 GTP-binding protein RAD_Q66P_mutation Human genes 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 7
- 102220585589 Short-chain dehydrogenase/reductase family 42E member 1_Q63P_mutation Human genes 0.000 claims 7
- 102220361097 c.307C>T Human genes 0.000 claims 5
- 230000003278 mimic effect Effects 0.000 claims 5
- 102220013742 rs397516741 Human genes 0.000 claims 5
- 102220257864 rs1050971384 Human genes 0.000 claims 4
- 102220198136 rs1057519882 Human genes 0.000 claims 4
- 102200116701 rs115206969 Human genes 0.000 claims 4
- 102220250913 rs1364636517 Human genes 0.000 claims 4
- 102220624338 Interferon alpha-8_T51A_mutation Human genes 0.000 claims 3
- 102220492589 Protein numb homolog_S48D_mutation Human genes 0.000 claims 3
- 102220477170 Y-box-binding protein 2_S102A_mutation Human genes 0.000 claims 3
- 102220364119 c.148C>A Human genes 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 102200007406 rs148775298 Human genes 0.000 claims 3
- 102200017902 rs267606847 Human genes 0.000 claims 3
- 102220252689 rs373178770 Human genes 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102220492635 Integrin alpha-3_D52Y_mutation Human genes 0.000 claims 2
- 102100040418 Tumor protein D52 Human genes 0.000 claims 2
- 102220555263 Tumor protein D52_D52Y_mutation Human genes 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102220487428 Actin-related protein 2/3 complex subunit 3_R90K_mutation Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 229940123189 CD40 agonist Drugs 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 102220349284 c.287A>T Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 102200160087 rs1131692231 Human genes 0.000 claims 1
- 102220126393 rs886044243 Human genes 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462035316P | 2014-08-08 | 2014-08-08 | |
| US62/035,316 | 2014-08-08 | ||
| US201562150789P | 2015-04-21 | 2015-04-21 | |
| US62/150,789 | 2015-04-21 | ||
| PCT/US2015/044356 WO2016022994A2 (en) | 2014-08-08 | 2015-08-07 | High affinity pd-1 agents and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525354A JP2017525354A (ja) | 2017-09-07 |
| JP2017525354A5 true JP2017525354A5 (cg-RX-API-DMAC7.html) | 2018-09-13 |
| JP6945444B2 JP6945444B2 (ja) | 2021-10-06 |
Family
ID=55264785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505807A Active JP6945444B2 (ja) | 2014-08-08 | 2015-08-07 | 高親和性ｐｄ−１薬剤とその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9546206B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3699189A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6945444B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107108707A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2994927A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1123385T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3177640T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2819451T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20201153T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE050406T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3177640T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3177640T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016022994A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| PL3177640T3 (pl) * | 2014-08-08 | 2020-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania |
| CN107074952B (zh) | 2014-09-30 | 2021-04-09 | 英特维特国际股份有限公司 | 结合犬pd-l1的pd-l1抗体 |
| EA037590B1 (ru) | 2014-11-25 | 2021-04-19 | Бристол-Майерс Сквибб Компани | Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации |
| CA2968961A1 (en) | 2014-11-25 | 2016-06-02 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of biologics |
| RU2688692C2 (ru) * | 2015-03-02 | 2019-05-22 | Инновейтив Целлюлар Терапевтикс КО., ЛТД. | Фармацевтическая композиция, обладающая противоопухолевым эффектом, и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека |
| IL283764B2 (en) * | 2015-04-10 | 2024-01-01 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| CN114634943A (zh) | 2015-05-18 | 2022-06-17 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| WO2017011580A2 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| BR112018000917A2 (pt) | 2015-07-16 | 2018-09-11 | Bioxcel Therapeutics Inc | abordagem inovadora para o tratamento de câncer através da imunomodulação |
| ES2881771T3 (es) | 2015-08-07 | 2021-11-30 | Alx Oncology Inc | Constructos que tienen un dominio de SIRP-alfa o variante del mismo |
| EP3352800B1 (en) * | 2015-09-24 | 2022-01-05 | The University of North Carolina at Chapel Hill | Methods and compositions for reducing metastases |
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| KR20190006495A (ko) | 2016-04-15 | 2019-01-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd80 변이체 면역조절 단백질 및 그의 용도 |
| KR20230051602A (ko) | 2016-04-15 | 2023-04-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| US11352413B2 (en) * | 2016-05-17 | 2022-06-07 | Albert Einstein College Of Medicine | Engineered PD-1 variants |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| JP7016323B2 (ja) | 2016-06-01 | 2022-02-21 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影 |
| RU2656181C1 (ru) * | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018027252A1 (en) * | 2016-08-11 | 2018-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
| US11447550B2 (en) * | 2016-10-04 | 2022-09-20 | The Curators Of The University Of Missouri | Peptides for molecular detection of PD-L1 |
| GB2564823B8 (en) | 2016-10-07 | 2022-06-29 | Tcr2 Therapeutics Inc | Compositions and methods for TCR reprogramming using fusion proteins |
| SI3535298T1 (sl) | 2016-11-02 | 2022-01-31 | Jounce Therapeutics, Inc. | Protitelesa proti pd-1 in njihove uporabe |
| WO2018089556A1 (en) | 2016-11-09 | 2018-05-17 | Healthtell Inc. | Coatings with tunable amine density |
| CA3043373A1 (en) | 2016-11-09 | 2018-05-17 | Healthtell Inc. | Pre-assembled, protected, chemically stable, chemoselective linkers |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US10736976B2 (en) | 2016-12-01 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| IL267862B2 (en) | 2017-01-05 | 2024-05-01 | Kahr Medical Ltd | A SIRPalpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF |
| HRP20230937T1 (hr) * | 2017-01-05 | 2023-11-24 | Kahr Medical Ltd. | Pd1-41bbl fuzijski protein i metode korištenja istog |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| WO2018170026A2 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| EP3596115A1 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
| WO2018183488A1 (en) * | 2017-03-28 | 2018-10-04 | Ohio State Innovation Foundation | Human pd1 peptide vaccines and uses thereof |
| WO2018192443A1 (zh) * | 2017-04-17 | 2018-10-25 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种多肽及其应用 |
| AU2018256436B2 (en) | 2017-04-19 | 2024-12-05 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| EP3630148A4 (en) * | 2017-05-26 | 2021-06-16 | The Johns Hopkins University | MULTIFUNCTIONAL ANTIBODY LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE |
| MY197688A (en) | 2017-07-24 | 2023-07-05 | Regeneron Pharma | Anti-cd8 antibodies and uses thereof |
| WO2019040098A1 (en) * | 2017-08-21 | 2019-02-28 | Dana-Farber Cancer Institute, Inc. | METHODS OF MODULATING THE INTERACTION BETWEEN BAF COMPLEXES AND EWS-FLI1 |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SG11202003078VA (en) | 2017-10-18 | 2020-05-28 | Alpine Immune Sciences Inc | Variant icos ligand immunomodulatory proteins and related compositions and methods |
| AU2018351006B2 (en) | 2017-10-18 | 2024-08-29 | Forty Seven, LLC | Anti-CD47 agent-based ovarian cancer therapy |
| CN107916255B (zh) * | 2017-11-16 | 2021-06-04 | 复旦大学 | Pdl-1基因靶向特异性甲基化表观遗传修饰抗肿瘤分子及其用途 |
| BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
| CN112292138A (zh) | 2018-01-22 | 2021-01-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | Car t细胞的使用方法 |
| CN112153984A (zh) | 2018-01-30 | 2020-12-29 | 福宏治疗公司 | 化合物及其用途 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| CN108794619B (zh) * | 2018-05-31 | 2021-09-17 | 郑州大学 | 一种高亲和pd-1蛋白突变体 |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| KR20210056288A (ko) | 2018-06-01 | 2021-05-18 | 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 | 질환 또는 병태를 치료하기 위한 조성물 및 그의 용도 |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| BR112021000360A2 (pt) | 2018-07-11 | 2021-04-13 | Kahr Medical Ltd. | Proteína de fusão variante sirpalpha-4-1bbl e métodos de uso da mesma |
| CA3104778A1 (en) * | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| CN108997492B (zh) * | 2018-07-19 | 2022-04-12 | 海珂分子（北京）科技有限责任公司 | 高亲和力的pd1胞外区突变体多肽及相关融合蛋白 |
| WO2020056085A1 (en) * | 2018-09-14 | 2020-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Spd-1 variant - fc fusion proteins |
| WO2020068500A1 (en) * | 2018-09-26 | 2020-04-02 | Albert Einstein College Of Medicine | Mutant variants of pd-1 receptor with selective binding to pd-l1 and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US20220010301A1 (en) * | 2018-11-14 | 2022-01-13 | Cowper Sciences Inc. | Methods of selecting functional interface mimics, and compositions thereof |
| KR102686295B1 (ko) | 2018-11-21 | 2024-07-19 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 아데노바이러스 및 아데노바이러스의 사용 방법 |
| CN111100199B (zh) * | 2018-12-29 | 2021-02-12 | 北京百普赛斯生物科技股份有限公司 | 一种荧光素标记的蛋白四聚体及其制备方法与应用 |
| WO2020151572A1 (en) | 2019-01-23 | 2020-07-30 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-pd-l1 diabodies and the use thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN111714618B (zh) * | 2019-03-22 | 2024-07-12 | 香雪生命科学技术（广东）有限公司 | T细胞和高亲和力pd-1融合蛋白的组合 |
| CN110054701B (zh) * | 2019-04-17 | 2022-12-27 | 中国医学科学院血液病医院（血液学研究所） | 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用 |
| CN113710694A (zh) | 2019-04-29 | 2021-11-26 | 梅奥医学教育及研究基金会 | 用于治疗癌症的多价pd-l1结合化合物 |
| KR20220016475A (ko) | 2019-05-01 | 2022-02-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법 |
| EP3962519A1 (en) | 2019-05-01 | 2022-03-09 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| JP7710997B2 (ja) | 2019-05-31 | 2025-07-22 | エーエルエックス オンコロジー インコーポレイテッド | 免疫チェックポイント阻害剤と組み合わせてｓｉｒｐアルファｆｃ融合によりがんを治療する方法 |
| CN112279923B (zh) * | 2019-07-22 | 2023-07-18 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体及其应用 |
| CN115151267B (zh) * | 2019-11-14 | 2025-03-25 | 路德维格癌症研究所 | 用于免疫治疗的组合物和方法 |
| JP7650047B2 (ja) * | 2019-11-27 | 2025-03-24 | 株式会社 MiyaCare Therapeutics | 変異型結合性タンパク質の製造方法及び変異型ｐｄ－１ |
| JP7561195B2 (ja) | 2020-01-29 | 2024-10-03 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| KR102623161B1 (ko) * | 2020-10-08 | 2024-01-09 | 고려대학교 산학협력단 | Pd-l1 친화도가 증가된 pd-1 변이체 |
| US12473349B2 (en) | 2020-05-06 | 2025-11-18 | Korea University Research And Business Foundation | PD-1 variants having increased PD-L1 affinity |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| EP4157869A4 (en) * | 2020-05-28 | 2024-06-26 | The Board of Trustees of the Leland Stanford Junior University | AEROSOL MUCUS-ATTACHING NANOBODIES TO PROTECT AGAINST VIRAL AND MICROBIAL CONTAMINATION IN CLOSED AND SEMI-CLOSED SPACES |
| WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| EP4243852A4 (en) * | 2020-11-13 | 2024-12-11 | Ludwig Institute for Cancer Research Ltd | PD-1 DECOY VARIANTS FOR IMMUNOTHERAPY |
| CN112999368A (zh) * | 2021-04-09 | 2021-06-22 | 广东药康生物科技有限公司 | 人源化模型进行药效评价方法的建立 |
| IL308400A (en) | 2021-05-13 | 2024-01-01 | Alx Oncology Inc | Combined therapies for cancer treatment |
| WO2023097313A1 (en) * | 2021-11-26 | 2023-06-01 | Vita Therapeutics, Inc. | Immune cell therapy of pd-l1 positive cancers |
| CN117777303A (zh) * | 2022-09-27 | 2024-03-29 | 北京大学 | 一种高亲和力pd1蛋白偶联物及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ES2197145T3 (es) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | Transferencia de genes mediada por adenovirus al gastrointestinal. |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| HU223733B1 (hu) | 1993-10-25 | 2004-12-28 | Canji, Inc. | Rekombináns adenovírus vektor és eljárás alkalmazására |
| CA2143491C (en) * | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| EP1083231A1 (en) | 1999-09-09 | 2001-03-14 | Introgene B.V. | Smooth muscle cell promoter and uses thereof |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| US7169874B2 (en) | 2001-11-02 | 2007-01-30 | Bausch & Lomb Incorporated | High refractive index polymeric siloxysilane compositions |
| CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| EP2350129B1 (en) * | 2008-08-25 | 2015-06-10 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| EP2328919A2 (en) * | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| JP5520961B2 (ja) | 2008-11-28 | 2014-06-11 | エモリー ユニバーシティ | 感染症および腫瘍を処置するための方法 |
| US20110189743A1 (en) * | 2009-10-06 | 2011-08-04 | Bio Architecture Lab, Inc. | Microbial systems for producing commodity chemicals |
| WO2012062218A1 (en) | 2010-11-11 | 2012-05-18 | The University Of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| PT2699264T (pt) * | 2011-04-20 | 2018-05-23 | Medimmune Llc | Anticorpos e outras moléculas que ligam b7-h1 e pd-1 |
| TWI835048B (zh) * | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| PT2804617T (pt) | 2012-01-17 | 2020-09-10 | Univ Leland Stanford Junior | Reagentes sirp-alfa de alta afinidade |
| JP2015506372A (ja) | 2012-01-27 | 2015-03-02 | グリックニック インコーポレイテッド | ＩｇＧ２ヒンジドメインを含む融合タンパク質 |
| EP2855666B1 (en) | 2012-05-25 | 2019-12-04 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| EP2890715B1 (en) | 2012-08-03 | 2020-12-16 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| EP2903637B1 (en) | 2012-10-02 | 2019-06-12 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| SI2931752T1 (sl) | 2012-12-17 | 2019-12-31 | Trillium Therapeutics Inc. | Zdravljenje bolezenskih celic CD47+ s fuzijami ALFA-FC SIRP |
| WO2014124217A1 (en) | 2013-02-07 | 2014-08-14 | Albert Einstein College Of Medicine Of Yeshiva University | A selective high-affinity immune stimulatory reagent and uses thereof |
| EP3811954A1 (en) | 2013-02-26 | 2021-04-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| PL3177640T3 (pl) * | 2014-08-08 | 2020-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania |
| CA2994935A1 (en) * | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
-
2015
- 2015-08-07 PL PL15829652T patent/PL3177640T3/pl unknown
- 2015-08-07 US US14/821,589 patent/US9546206B2/en active Active
- 2015-08-07 EP EP20166891.0A patent/EP3699189A1/en active Pending
- 2015-08-07 US US15/502,439 patent/US10800830B2/en active Active
- 2015-08-07 JP JP2017505807A patent/JP6945444B2/ja active Active
- 2015-08-07 HR HRP20201153TT patent/HRP20201153T1/hr unknown
- 2015-08-07 EP EP15829652.5A patent/EP3177640B1/en active Active
- 2015-08-07 WO PCT/US2015/044356 patent/WO2016022994A2/en not_active Ceased
- 2015-08-07 CA CA2994927A patent/CA2994927A1/en active Pending
- 2015-08-07 ES ES15829652T patent/ES2819451T3/es active Active
- 2015-08-07 DK DK15829652.5T patent/DK3177640T3/da active
- 2015-08-07 HU HUE15829652A patent/HUE050406T2/hu unknown
- 2015-08-07 PT PT158296525T patent/PT3177640T/pt unknown
- 2015-08-07 CN CN201580054333.5A patent/CN107108707A/zh active Pending
- 2015-11-03 US US14/931,725 patent/US9562087B2/en active Active
-
2020
- 2020-05-26 US US16/883,396 patent/US11814419B2/en active Active
- 2020-08-05 CY CY20201100728T patent/CY1123385T1/el unknown
-
2023
- 2023-10-06 US US18/482,223 patent/US20240174729A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525354A5 (cg-RX-API-DMAC7.html) | ||
| Xiang et al. | Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 | |
| Hansen et al. | Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail | |
| Kato et al. | Structural analysis of RIG-I-like receptors reveals ancient rules of engagement between diverse RNA helicases and TRIM ubiquitin ligases | |
| Muzioł et al. | Structural basis for budding by the ESCRT-III factor CHMP3 | |
| Ketema et al. | Requirements for the localization of nesprin-3 at the nuclear envelope and its interaction with plectin | |
| Di Giovine et al. | Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1 | |
| Liu et al. | A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection | |
| Dreyfus et al. | Highly conserved protective epitopes on influenza B viruses | |
| Chi et al. | An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants | |
| Li et al. | A molecular-level account of the antigenic hantaviral surface | |
| Peng et al. | Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody | |
| Morgan et al. | Syndecan-4 phosphorylation is a control point for integrin recycling | |
| Sillibourne et al. | Primary ciliogenesis requires the distal appendage component Cep123 | |
| Burgo et al. | A molecular network for the transport of the TI-VAMP/VAMP7 vesicles from cell center to periphery | |
| Friedrich et al. | DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety | |
| Sickmier et al. | The panitumumab EGFR complex reveals a binding mechanism that overcomes cetuximab induced resistance | |
| Pal et al. | Structural basis for phosphorylation-dependent recruitment of Tel2 to Hsp90 by Pih1 | |
| van Dinther et al. | Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling | |
| Håberg et al. | SNX18 is an SNX9 paralog that acts as a membrane tubulator in AP-1-positive endosomal trafficking | |
| Tousley et al. | Huntingtin associates with the actin cytoskeleton and α-actinin isoforms to influence stimulus dependent morphology changes | |
| van Roeyen et al. | Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities | |
| HRP20201153T1 (hr) | Pd-1 sredstva visokog afiniteta i načini uporabe | |
| JP2018519296A5 (cg-RX-API-DMAC7.html) | ||
| JP2017061471A5 (cg-RX-API-DMAC7.html) |